PR Newswire

U.S. FDA Approves Clinical Trial Application for IASO Bio's BCMA CAR-T CT103A for Relapsed/Refractory Multiple Myeloma

Written by PR Newswire

$U.S. FDA Approves Clinical Trial Application for IASO Bio's BCMA CAR-T CT103A for Relapsed/Refractory Multiple Myeloma$

SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 22, 2022 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products,, today announced that the Investigational New Drug (IND) application for its in-house...

U.S. FDA Approves Clinical Trial Application for IASO Bio's BCMA CAR-T CT103A for Relapsed/Refractory Multiple Myeloma

The Factors Influencing PPF Wrap Costs: …

A Complete Checklist for Hiring Reliable…

A solid investment: 5 awesome benefits o…

6 Simple Steps to Making a Worker’s Comp…

8 innovative smart home security ideas t…

The Bulletin Magazine

Professional Removalists Melbourne: Your Trusted Experts for a Smooth, Stress-Free Move

How Lawyers in Melbourne Can Resolve Disputes Without Going to Court

Multi Unit Development Builders Melbourne: Maximising Land and Investment Potential

A Complete Checklist for Hiring Reliable Home Removalists in Perth

What is the Difference between Roadside Assistance and Towing?

Don't Renew Your Roadside Assistance Cover Until You Read This!

eCommerce Site Design: Building Modern, High-Performing Online Stores for Australian Businesses

Your Reliable Partner for Every Roadside Emergency

Choosing Waterproofing Membranes for Outdoor Spaces: The Essential Attributes You Need

How Modular Content Accelerates Turnaround for Time-Sensitive Campaigns

How Litigation Lawyers in Sydney Can Help Resolve Disputes Efficiently

Revitalising Homes and Offices with Professional Carpet Cleaning Melbourne